Dr Paul Thomas

Dr Paul Thomas

Dr Paul Thomas is an award-winning Dartmouth-trained pediatrician with nearly 30 years experience. Along his journey he began to question the vaccines and the ever growing CDC schedule of doses and in time he co-author of the book, The Vaccine-Friendly…

“Classical” herd immunity may not be attainable for COVID-19

On March 21, 2022, Dr Anthony Fauci et al published a paper to further propagate the notion  that "classical herd immunity" may not be "attainable" for COVID-19.  "The authors explain how the scientific understanding of herd immunity and its applications to various diseases have evolved over time." [1] Some factors that Dr Fauci et al believe hinder achieving herd immunity for SARS-CoV-2 include: "the virus’ ability to continually mutate to new variants; asymptomatic virus transmission, which complicates public health control strategies; the inability of prior infection or vaccination to provide durable protection against reinfection; suboptimal vaccination coverage; and adherence to non-pharmacologic interventions." "Research to develop pan-coronavirus vaccines, which could protect against multiple coronaviruses or at least multiple SARS-CoV-2 variants, remains crucial."  Remember in March 2020 getting a vaccine was the only way, this is the next step!  [2] Ten days later, on March 31st, the NIH launched their clinical trials for mRNA multi-variant vaccines; a solution they'll likely come to promote!
Oxford-AstraZeneca COVID-19 vaccine

AstraZeneca COVID-19 Vaccine

The Oxford-AstraZeneca COVID-19 vaccine was developed and tested in partnership with The University of Oxford an the British-Swedish company AstraZeneca - a coronavirus vaccine originally known as ChAdOx1 nCoV-19 but when AstraZeneca took over it was relabled AZD1222. [1] The…

CDC confirms first person-to-person spread of 2019-nCoV

On January 30, 2020 the CDC confirmed that the 2019 Novel Coronavirus (2019-nCoV) had spread from an infected person [woman from Chicago] to a house hold member [husband], representing the first instance of person-to-person transmission in the US, involving someone who had not traveled to China.  He is the 6th case in the US. [1, 2] "Previously, all confirmed U.S. cases had been associated with travel to Wuhan, China," this latest case has no history of travel to Wuhan, "but shared a household with the patient diagnosed with 2019-nCoV infection on January 21, 2020." "Officials warned that the case of human-to-human transmission indicated that the coronavirus was a “very serious public health situation.”

China’s CDC director “confirms” seafood market animal as source of SARS-CoV-2

According to China media, on January 23, 2020 at a government briefing on the coronavirus outbreak the Director of the Chinese CDC, Gao Fu stated about the virus origin: "We have confirmed it was transmitted via wild animals illegally sold at a seafood market in Wuhan. At first, it was spread from animals to humans. However, the virus has since been mutating and has become adaptive to its host. Human-to-human transmission has occurred, and there has been some community transmission. That is to say, it has gone through three stages." No evidence is provided as to which specific zoonotic source, wild animal(s) that is. In the weeks following this proclamation the media, public health and even scientists around the world  used this claim to begin reporting about the threat of animal to human (zoonotic) diseases from seafood markets, such as Australia's 60 Minutes. On March 26, 2020 in a report the WHO were unable to identify the origin of the virus, only environmental samples taken at the seafood market were positive for SARS-CoV-2, no animal. By mid-2021, after 18 months and almost 3 million viruses sequenced in Hubei, China and world wide, the WHO investigation were unable to find a..> READ MORE

FDA grants EUA for Moderna’s COVID-19 vaccine

On December 18, 2020 the U.S. Food and Drug Administration (FDA) announced they have "issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older."  The FDA stated the "vaccine was 94.1% effective in preventing COVID-19 disease among these clinical trial participants with 11 cases of COVID-19 in the vaccine group and 185 in the placebo group." This comes the day after the December 17, 2020  VRBPAC meeting where they discussed the EUA of the Moderna COVID-19 Vaccine “for the prevention of COVID-19 in individuals 18 years and older.” This EUA is granted 4 days after the first Pfizer-BioNTech vaccines was administered in the US and 10 days before the WHO declares the virus endemic the vaccines likely not to stop transmission!